Gene therapy for Parkinson’s disease: where are we now and where are we going?

References

• Aposhian HV. The use of DNA for gene therapy – the need, experimental approach, and implications. Perspect. Biol. Med.14(1), 98–108 (1970).
   PubMed Web of Science ®Google Scholar
• Fox MS, Littlefield JW. Reservations concerning gene therapy. Science173(993), 195 (1971).
   Google Scholar
• Osterman JV, Waddell A, Aposhian HV. Gene therapy systems: the need, experimental approach, and implications. Ann. NY Acad. Sci.179, 514–519 (1971).
   PubMed Web of Science ®Google Scholar
• Qasba PK, Aposhian HV. DNA and gene therapy: transfer of mouse DNA to human and mouse embryonic cells by polyoma pseudovirions. Proc. Natl Acad. Sci. USA68(10), 2345–2349 (1971).
   Google Scholar
• Rogers S. Gene therapy: a potentially invaluable aid to medicine and mankind. Res. Commun. Chem. Pathol. Pharmacol.2(4), 587–600 (1971).
   Google Scholar
• Freese E. Prospects of gene therapy. Science175(25), 1024–1025 (1972).
   Google Scholar
• Friedmann T, Roblin R. Gene therapy for human genetic disease? Science175(25), 949–955 (1972).
   PubMed Web of Science ®Google Scholar
• Frank SA, Wilson R, Holloway RG et al. Ethics of sham surgery: perspective of patients. Mov. Disord.23(1), 63–68 (2008).
   Google Scholar
• Kim SY, Holloway RG, Frank S et al. Volunteering for early phase gene transfer research in Parkinson disease. Neurology66(7), 1010–1015 (2006).
   Google Scholar
• Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY. Long term understanding of study information in research participants with Parkinson’s disease. Parkinsonism Relat. Disord.16(1), 60–63 (2010).
   Google Scholar
• Kaplitt MG, Feigin A, Tang C et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, Phase I trial. Lancet369(9579), 2097–2105 (2007).
   PubMed Web of Science ®Google Scholar
• Azzouz M, Martin-Rendon E, Barber RD et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson’s disease. J. Neurosci.22(23), 10302–10312 (2002).
   PubMed Web of Science ®Google Scholar
• Jarraya B, Boulet S, Ralph GS et al. Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med.1(2), 2ra4 (2009).
   PubMed Web of Science ®Google Scholar
• Perlmutter JS, Mink JW. Deep brain stimulation. Annu. Rev. Neurosci.29, 229–257 (2006).
   PubMed Web of Science ®Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol.8(1), 67–81 (2009).
   PubMed Web of Science ®Google Scholar
• Levy R, Lang AE, Dostrovsky JO et al. Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. Brain124(Pt 10), 2105–2118 (2001).
   PubMed Web of Science ®Google Scholar
• Chen L, Xie JX, Fung KS, Yung WH. Zolpidem modulates GABA(A) receptor function in subthalamic nucleus. Neurosci. Res.58(1), 77–85 (2007).
   PubMed Web of Science ®Google Scholar
• Luo J, Kaplitt MG, Fitzsimons HL et al. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science298(5592), 425–429 (2002).
   PubMed Web of Science ®Google Scholar
• Zander JF, Munster-Wandowski A, Brunk I et al. Synaptic and vesicular coexistence of VGLUT and VGAT in selected excitatory and inhibitory synapses. J. Neurosci.30(22), 7634–7645 (2010).
   PubMed Web of Science ®Google Scholar
• Galvan A, Charara A, Pare JF, Levey AI, Smith Y. Differential subcellular and subsynaptic distribution of GABA(A) and GABA(B) receptors in the monkey subthalamic nucleus. Neuroscience127(3), 709–721 (2004).
   Google Scholar
• Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron7(1), 91–100 (1991).
   PubMed Web of Science ®Google Scholar
• Emborg ME, Carbon M, Holden JE et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab.27(3), 501–509 (2007).
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Daadi M, Pivirotto P et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp. Neurol.197(2), 363–372 (2006).
   Google Scholar
• Forsayeth JR, Eberling JL, Sanftner LM et al. A dose-ranging study of AAV–hAADC therapy in parkinsonian monkeys. Mol. Ther.14(4), 571–577 (2006).
   Google Scholar
• Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2–hAADC. Mol. Ther.18(8), 1458–1461 (2010).
   PubMed Web of Science ®Google Scholar
• Eberling JL, Jagust WJ, Christine CW et al. Results from a Phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology70(21), 1980–1983 (2008).
   PubMed Web of Science ®Google Scholar
• Christine CW, Starr PA, Larson PS et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology73(20), 1662–1669 (2009).
   PubMed Web of Science ®Google Scholar
• DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA. J. Nucl. Med.38(4), 630–636 (1997).
   PubMedGoogle Scholar
• Jordan S, Eberling JL, Bankiewicz KS et al. 6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res.750(1–2), 264–276 (1997).
   Google Scholar
• Doudet DJ, Chan GL, Jivan S et al. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J. Cereb. Blood Flow Metab.19(3), 278–287 (1999).
   Google Scholar
• Bankiewicz KS, Forsayeth J, Eberling JL et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther.14(4), 564–570 (2006).
   PubMed Web of Science ®Google Scholar
• Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science260(5111), 1130–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J. The GDNF family ligands and receptors – implications for neural development. Curr. Opin. Neurobiol.10(1), 103–110 (2000).
   PubMed Web of Science ®Google Scholar
• Akerud P, Alberch J, Eketjall S, Wagner J, Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J. Neurochem.73(1), 70–78 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenblad C, Kirik D, Devausx B, Moffat B, Phillips HS, Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci.111, 1554–1566 (1999).
   Google Scholar
• Fiandaca M, Forsayeth J, Bankiewicz K. Current status of gene therapy trials for Parkinson’s disease. Exp. Neurol.209(1), 51–57 (2008).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Herzog CD, Dass B et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol.60(6), 706–715 (2006).
   PubMed Web of Science ®Google Scholar
• Eberling JL, Kells AP, Pivirotto P et al. Functional effects of AAV2–GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum. Gene Ther.20(5), 511–518 (2009).
   Google Scholar
• Su X, Kells AP, Huang EJ et al. Safety evaluation of AAV2–GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum. Gene Ther.20(12), 1627–1640 (2009).
   PubMed Web of Science ®Google Scholar
• Kells AP, Eberling J, Su X et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2–GDNF. J. Neurosci.30(28), 9567–9577 (2010).
   PubMed Web of Science ®Google Scholar
• Johnston LC, Eberling J, Pivirotto P et al. Clinically relevant effects of convection-enhanced delivery of AAV2–GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene Ther.20(5), 497–510 (2009).
   Google Scholar
• Manfredsson FP, Tumer N, Erdos B et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol. Ther.17(6), 980–991 (2009).
   PubMed Web of Science ®Google Scholar
• Palfi S, Leventhal L, Chu Y et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci.22(12), 4942–4954 (2002).
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Ostrem JL, Verhagen L et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, Phase I trial. Lancet Neurol.7(5), 400–408 (2008).
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Forsayeth J, Mirek H et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum. Gene Ther.20(3), 225–237 (2009).
   PubMed Web of Science ®Google Scholar
• Chirmule N, Xiao W, Truneh A et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol.74(5), 2420–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Sanftner LM, Suzuki BM, Doroudchi MM et al. Striatal delivery of rAAV–hAADC to rats with preexisting immunity to AAV. Mol. Ther.9(3), 403–409 (2004).
   PubMed Web of Science ®Google Scholar
• Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol.78(12), 6344–6359 (2004).
   PubMed Web of Science ®Google Scholar
• Peden CS, Manfredsson FP, Reimsnider SK et al. Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol. Ther.17(3), 524–537 (2009).
   Google Scholar
• Wright JF, Qu G, Tang C, Sommer JM. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr. Opin. Drug Discov. Devel.6(2), 174–178 (2003).
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Yamashita Y, Mirek H et al. The ‘perivascular pump’ driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther.14(1), 69–78 (2006).
   PubMed Web of Science ®Google Scholar
• Passini MA, Macauley SL, Huff MR et al. AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol. Ther.11(5), 754–762 (2005).
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science301(5634), 839–842 (2003).
   PubMed Web of Science ®Google Scholar
• Hollis ER 2nd, Jamshidi P, Lorenzana AO et al. Transient demyelination increases the efficiency of retrograde AAV transduction. Mol. Ther.18(8), 1496–1500 (2010).
   Google Scholar
• Arvidsson A, Kirik D, Lundberg C et al. Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiol. Dis.14(3), 542–556 (2003).
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Mirek H, Bringas J, Cunningham J, Bankiewicz K. Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum. Gene Ther.15(5), 469–479 (2004).
   PubMed Web of Science ®Google Scholar
• Kells AP, Hadaczek P, Yin D et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl Acad. Sci. USA106(7), 2407–2411 (2009).
   Google Scholar
• Krauze MT, Saito R, Noble C et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg.103(5), 923–929 (2005).
   PubMed Web of Science ®Google Scholar
• Varenika V, Dickenson P, Bringas J et al. Real-time imaging of CED in the brain permits detection of infusate leakage. J. Neurosurg.109, 874–880 (2008).
   PubMed Web of Science ®Google Scholar
• Fiandaca MS, Varenika V, Eberling J et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage47(Suppl. 2), T27–T35 (2009).
   PubMed Web of Science ®Google Scholar
• Yin D, Valles FE, Fiandaca MS et al. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage187(1), 46–51 (2009).
   Google Scholar
• Yin D, Richardson RM, Fiandaca MS et al. Cannula placement for effective convection-enhanced delivery in the non-human primate thalamus and brainstem: implications for clinical delivery of therapeutics. J. Neurosurg.113(2), 240–248 (2010).
   Google Scholar